

## CLINICAL TRIALS AT THE BANK OF CYPRUS ONCOLOGY CENTRE

### Currently recruiting trials or on halt for recruitment until further notice

YEAR OPENED	TRIAL NAME	Investigator(s)	STATUS
2013	Development of a module to supplement the <b>EORTC</b> Core instruments for assessment of Health Related Quality of Life in patients with Anal Cancer (phases I-IV)	Dr. Vasiliou	Recruitment open
2013	Creation of symptom based questionnaires based on current guidelines for module development: the development of a time-efficient procedure GIST <b>EORTC</b> (phases I-IV)	Dr. Vasiliou	Recruitment open
2014	Adaptation of the <b>EORTC</b> IN-PATSAT32 in a core cancer patient satisfaction with care questionnaire (PATSAT-CORE x items) and development of a complimentary module for the outpatient setting (phases I-IV)	Dr. Vasiliou	Recruitment open
2015	Development of an <b>EORTC</b> cancer survivorship quality of life questionnaire (Phase I-IV)	Dr. Vasiliou	Recruitment open
2017	Development of an <b>EORTC</b> quality of life questionnaire for patients with Pancreatic Neuroendocrine Tumors (P-Net): Phases I-III	Dr. Vasiliou Dr. Papamichael Dr. Kountourakis	Recruitment open
2017	Development of an <b>EORTC</b> questionnaire for individuals at risk for a Hereditary Cancer Predisposition Syndrome: the EORTC QLQ-HCPS	Dr. Vasiliou	Recruitment open
2019	Single-arm phase II study of panitumumab rechallenge in combination with oxaliplatin or irinotecan-based chemotherapy in patients with RAS wild type advanced colorectal cancer (A-REPEAT) - <b>HeCOG</b>	Dr. Papamichael Dr. Kountourakis	Recruitment open
2020	IMMUcan falls under the platform "SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access- <b>EORTC</b>	Dr. Papamichael	Recruitment open
2020	A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy- <b>ROCHE - CUPISCO</b>	Dr. Papanastasopoulos	Recruitment open

**New trials coming soon...**

<b>YEAR OPENED</b>	<b>TRIAL NAME</b>	<b>Investigator(s)</b>	<b>STATUS</b>
2021	Molecular characterization of rare cancers – Arcagen” which falls under the platform “SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access- <b>EORTC</b>	Dr. Papamichael	Awaiting for Site Initiation
2021	A randomized phase III study of neoadjuvant chemotherapy followed by surgery alone for patients with High Risk RetroPeritoneal Sarcoma - EORTC	Dr. Constantinidou	EC/CA pending
2021	Sourasky Medical Centre ReX-C system implementation in patients receiving home-based oral oncolytic therapy	Dr. Marcou	Coming soon

**Projects funded by local funding bodies e.g. RIF or through EU funding  
(Active or coming soon.....)**

YEAR OPENED	TRIAL NAME	Investigator(s)	STATUS
2018	Optimizing the diagnostic value of SPECT myocardial perfusion imaging under the influence of liver activity	Dr. Frangos	Active
2018	Optimizing the diagnostic value of postsurgical I-123 SPECT thyroid imaging and applying patient-specific dosimetry for radioiodine ablation of thyroid remnants	Dr. Frangos	Active
2019	Investigation of the <b>pre</b> dictive and prognostic role of <b>liquid</b> biopsies in NSCLC patients treated with the anti- PD-1 inhibitor Pembrolizumab – PRELIFE	Dr. Charalambous	Active
2019	Platform for Biosciences and human health in Cyprus: MicroCT Enabled and Synchrotron Radiation Enabled Analyses - BIOMERA	Dr. Andreopoulos Dr. Constantinidou	Active
2021	PREdictive BIOMarkers of response to immunotherapy and chemotherapy in patients with Advanced Solid Tumours (PREBIOM): A Non Interventional Study	Dr. Charalambous	Coming Soon
2021	An interdisciplinary approach for the management of the elderly multimorbid patient with breast cancer therapy induced cardiac toxicity – H2020- CARDIOCARE	Dr. Constantinidou Dr. Papamichael Dr. Marcou Dr. Kakouri	Active

**Recruitment closed but patients on treatment or follow – up**

YEAR OPENED	TRIAL NAME	Investigator(s)	STATUS
2011	(Colorectal Cancer Trial) - Is greater downstaging and tumour regression observed when surgery is delayed to 12 weeks after completion of Chemoradiotherapy vs 6 weeks? <b>Royal Marsden</b>	Dr. Vasiliou	Recruitment closed Follow - up
2016	A Disease Registry Study To Prospectively Observe Treatment Patterns And Outcomes In Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer – <b>ROCHE HELLAS (ML28801)</b>	Dr. Marcou Dr. Kakouri	Recruitment closed Follow - up
2016	A Phase II study of Switch Maintenance Pembrolizumab in patients with Non Small Cell Lung Cancer (NSCLC) who do not progress after First Line Platinum Doublet Chemotherapy - <b>BOCOC - SWIPE</b>	Dr. Charalambous	Recruitment closed Patient on treatment and Follow – up
2018	A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non-small cell lung cancer - <b>Merck KG - Javelin</b>	Dr. Charalambous Dr. Orfanos Dr. Kyriacou	Recruitment closed Query and closeout

**Older trials which are now closed**

YEAR OPENED	TRIAL NAME	Investigator(s)	YEAR CLOSED
1999	Multicenter international study of oxaliplatin/5fu-lv in the adjuvant treatment of colon cancer – “MOSAIC” study.	Dr. Papamichael	2006
2000	A randomised trial to assess the role of irinotecan and oxaliplatin in advanced colorectal cancer - focus-(MRC - Medical Research Council-Uk) “FOCUS” study.	Dr. Papamichael	2008
2000	Multicentre Phase III open label randomised trial comparing cpt-11 in combination with 5-fu/fa infusional regimen to the same 5 fu/fa infusional regimen alone as adjuvant treatment of stage III colon cancer“PETACC-3”	Dr. Papamichael	2008
2001	The international tirapazone triple trial	Dr. Papamichael	2003
2002	<sup>A</sup> Phase III, randomized efficacy and safety study of the combination chemotherapy with tirapazamine + cisplatin + vinorelbine in subjects with inoperable, previously untreated, non-small cell lung cancer.	Dr. Adamou	2003
2002	<sup>A</sup> multicenter Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T), with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) and with docetaxel, platinum salt and trastuzumab (TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the her2neu alteration. BCIRG (006)	Dr. Adamou Dr. Kakouri	2015
2002	A multicenter Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel ( AC-T ) as adjuvant treatment of operable breast cancer her2neu negative patients with positive axillary lymph nodes. BCIRG (005)	Dr. Adamou Dr. Kakouri	2014
2003	A randomized Phase III Study of follow up with or without adjuvant Gefitinib (Iressa) following chemotherapy in patients with advanced non-small cell lung cancer. EORTC (8021)	Dr. Papamichael Dr. Decatris	2012
2013	Screening Platform of the <b>EORTC</b> for Clinical Trials Advanced Colorectal cancer “SPECTAcOLOR”	Dr. Papamichael	2019

January 2021

2013	An open-label, extension (rollover) study of vemurafenib in patients with BRAFv600 mutation-positive malignancies previously enrolled in an antecedent vemurafenib protocol.	Dr. Orphanos/ Dr. Kordatou	2020
2003	Three dimensional conformal radiotherapy / intensity modulated radiotherapy alone vs three dimensional conformal therapy / intensity modulated radiotherapy plus adjuvant hormonal therapy in localized t1b-c, t2a, n0, m0 prostatic carcinoma. EORTC radiotherapy group – a Phase III randomized study EORTC (22991)	Dr. Kitsios	2014
2004	International prophylactic cranial irradiation trial. A multicenter randomized trial of high versus standard doses of prophylactic cranial irradiation in limited small cell lung cancer complete responders - EORTC (2003-08004) pc199-eulint1	Dr. Katodritis	2010
2004	Prophylactic cranial irradiation in extensive disease small cell lung cancer EORTC (22993-08993).	Dr. Katodritis	2010
2005	A randomized, open- label Phase II Study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI plus Cetuximab as first line therapy in patients with metastatic colorectal cancer. “CECOG” study	Dr. Papamichael	2008
2007	International, Randomized, Open-Label, Phase III Trial of Paclitaxel/Carboplatin plus PF3512676 versus Paclitaxel/Carboplatin alone as first-line treatment of patients with advanced non-small cell lung cancer. (A8501001)	Dr. Decatris	2008
2007	Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage postoperative external radiotherapy alone in pT3a-b R0-1 cN0M0 / pT2R1 cN0M0, Gleason score 5-10 prostatic carcinoma. A Phase III study EORTC (22043-30041)	Dr. Kitsios	2013
2007	A Multicenter, Randomized, Double-Blind, Phase III Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (Folfiri) As First Line Treatment. “THE SUN TRIAL”	Dr. Papamichael	2010

2008	A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients with Stage IIIb with effusion and Stage IV non-small cell lung cancer. "NEXUS" study.	Dr. Charalambous Dr. Decatris	2011
2008	A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for metastatic pancreatic cancer "VANILLA" study.	Dr. Papamichael	2011
2010	International Validation Study of the European Organization for Research and Treatment of Cancer Brain Module (EORTC-QLQ-BN20) Quality of Life group measure with EORTC-QLQ-C30 for Assessing Quality of Life in Patients with Brain Metastases: A study conducted on behalf of the EORTC (Quality of Life Questionnaire BN20-C30)	Dr. Vasiliou	2011
2010	International Cross-Cultural Field Validation of an EORTC Questionnaire Module for Patients with Bone Metastases EORTC (QLQ-BM22)	Dr. Vasiliou	2011
2011	An open-label, randomized, controlled, multi-center, Phase 1/11 trial investigating 2 EMD <b>525797</b> doses in combination with cetuximab + irinotecan versus cetuximab + irinotecan alone, as second-line treatment for subjects with k-ras wild type ( <b>WT</b> ) metastatic colorectal cancer (mCRC). Subjects with k-ras <b>WT</b> mCRC will be eligible for enrollment if they are refractory to or progressive after first-line chemotherapy with an oxaliplatin-containing therapeutic regimen "POSEIDON" study.	Dr. Papamichael	2014
2011	An International Field Study of the Reliability and Validity of an EORTC Older Person-Specific Quality of Life (QOL) Questionnaire Module (the EORTC QLQ-ELD15) and EORTC QLQ-C30 in assessing the QOL of cancer patients aged 70 years and above. EORTC (QLQ-ELD15 and QLQ-C30)	Dr. Vasiliou	2012
2011	A non-interventional follow-up to the MOSAIC study (multicentre international study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer) up to 10 years and translational research "MOSAIC EXTENSION"(C09-2)	Dr. Papamichael	2012

2012	Double blind randomized phase III study of maintenance pazopanib versus placebo in NSCLC patients, non progressive after first line chemotherapy. MAPPING, an EORTC Lung Group study.	Dr. Charalambous	2013
2012	BISphosphonates use in solid tumours. REGistry for collecting the impact of treatment of bone metastases from solid tumours	Dr. Kitsios	2015
2013	A phase I, open-label, multicentre, 3-period, fixed –sequence study to investigate the effect of Vemurafenib on the pharmacokinetics of a single dose of Tizanidine (A CYP1A2 Substrate) in patients with BRAF v600 mutation-positive metastatic malignancy	Dr. Decatris Dr. Orphanos Dr. Katodritis	2015
2013	A phase III prospective, two-cohort non-randomized, multi-centre, multinational, open label study to assess the safety of assisted- and self- administered subcutaneous Trastuzumab as therapy in patients with operable HER-2-positive early breast cancer [SafeHer Study]	Dr. Marcou	2013 (for CY)
2014	Update of the EORTC Questionnaire for assessing the quality of life in lung cancer patients (EORTC. QLQ – LC13)- (Phases I to IV)	Dr. Katodritis Dr. Vomvas Dr. Georgiou	2016
2014	Μελέτη φάσης II μιας ομάδας θεραπείας με aflibercept ως θεραπεία συντήρησης μετά από πρώτη γραμμής θεραπεία με FOLFIRI σε συνδυασμό με aflibercept σε ασθενείς με μεταστατικό κολορρηικό καρκίνο.	Dr. Kountourakis Dr. Papamichael	2015 (for CY)
2007	A two-arm phase II randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of patients with K-ras-normal (wild-type) metastatic colorectal cancer. “COIN-B” study MRC – CR-11	Dr. Papamichael	2017
2011	Monitoring response to systemic and regional chemotherapy using dynamic contrast enhanced ultrasonography DCE-US. Evaluation of Possible surrogate response markers for efficacy and toxicity.	Dr. Kountourakis Dr. Polyviou	2017
2012	A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer (IMM-101-002)	Dr. Papamichael Dr. Kountourakis	2017
2017	The impact of air pollution and the Mediterranean diet on lung cancer development in Cyprus - <b>BOCOC</b>	Dr. Charalambous	2017



2017	Investigation of the Increasing Incidence Trends of Thyroid Cancer in Cyprus - <b>BOCOC</b>	Dr. Charalambous Dr. Frangos	2017
2014	A Prospective, Multicenter, Randomized, Double Blind, Placebo controlled, 2-Parallel Groups, Phase 3 Study to compare the efficacy and safety of Masitinib in combination with Folfiri (Irinotecan, 5-Fluorouracil and Folinic Acid) to Placebo in combination with Folfiri In second line treatment of patients with Metastatic Colorectal Cancer	Dr. Papamichael Dr. Kountourakis	2017
2012	Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment. EORTC.	Dr. Papamichael	2018
2014	A prospective, multicenter, randomised, open-label, activecontrolled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imatinib - <b>AB Science</b>	Dr. Orphanos Dr. Papamichael	2018
2016	A multi-centre randomised clinical trial of biomarker-driven maintenance treatment for first-line metastatic colorectal cancer (MODUL) A Phase II study - <b>ROCHE HELLAS</b>	Dr. Papamichael Dr. Kountourakis Dr. Papanastasopoulos	2019
2017	Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma	Dr. Constantinidou Dr. Katodritis	2018
2016	A prospective, multicentre, double-blind, randomized, placebo-controlled, phase 3 study to evaluate efficacy and safety of masitinib with irinotecan in patients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy <b>AB SCIENCE</b>	Dr. Kountourakis Dr. Papamichael	Awaiting for Site Initiation Visit – on halt
2019	DKN-01/atezolizumab as second line treatment of biliary tract cancer and in combination or not with paclitaxel as second or third line treatment of esophagogastric cancer: a multicenter Phase II Trial- <b>EORTC</b>	Dr. Papanastasopoulos	Closed by the Sponsor globally 2020
2019	Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma. EORTC	Dr. Constantinidou	Stopped by EORTC